Advertisement
Advertisement
U.S. markets close in 3 hours 44 minutes
Advertisement
Advertisement
Advertisement
Advertisement

ZLAB Dec 2022 80.000 call

OPR - OPR Delayed Price. Currency in USD
1.88000.0000 (0.00%)
As of 02:17PM EST. Market open.
Advertisement
Full screen
Loading interactive chart...
  • Simply Wall St.

    Zai Lab Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags

    Zai Lab ( NASDAQ:ZLAB ) Third Quarter 2022 Results Key Financial Results Revenue: US$57.5m (up 34% from 3Q 2021). Net...

  • GlobeNewswire

    Zai Lab Announces Third Quarter 2022 Financial Results and Corporate Updates

    Revenue of $57.5 million for the third quarter of 2022, representing a 33% increase y-o-y and a 19% increase q-o-q; continued revenue growth led by ZEJULA Regional strategic collaboration for TIVDAK® (tisotumab vedotin) strengthens Zai Lab’s leadership in developing and providing access to medicine to treat women’s cancer in ChinaStrong balance sheet with a cash position of $1.12 billionCompany to host a conference call and webcast on November 10, 2022, at 8:00 a.m. ET SHANGHAI and CAMBRIDGE, Ma

  • GlobeNewswire

    Zai Lab to Present New Oncology Research at 2022 Society for Immunotherapy of Cancer Annual Meeting

    Poster presentations will highlight Zai’s key internal pipeline programs, ZL-1211 (anti-CLDN18.2 antibody) for gastric cancer and ZL-1218 (anti-CCR8 antibody) for solid tumorsSHANGHAI and CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, will present new data from its internal immuno-oncology pipeline at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Me

Advertisement
Advertisement